NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $16.26 +0.34 (+2.14%) Closing price 04:00 PM EasternExtended Trading$16.00 -0.27 (-1.63%) As of 05:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ARWR alerts:Sign Up Key Stats Today's Range$15.65▼$16.5250-Day Range$14.71▼$18.8852-Week Range$9.57▼$29.86Volume2.45 million shsAverage Volume1.97 million shsMarket Capitalization$2.25 billionP/E RatioN/ADividend YieldN/APrice Target$43.71Consensus RatingModerate Buy Company Overview Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California. Read More Arrowhead Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks78th Percentile Overall ScoreARWR MarketRank™: Arrowhead Pharmaceuticals scored higher than 78% of companies evaluated by MarketBeat, and ranked 212th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArrowhead Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to decrease in the coming year, from ($2.42) to ($3.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -11.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -11.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioArrowhead Pharmaceuticals has a PEG Ratio of 18.72. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 10.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arrowhead Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.55% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently decreased by 0.47%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG3.4 / 5Environmental Score-2.55 Percentage of Shares Shorted9.55% of the float of Arrowhead Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently decreased by 0.47%, indicating that investor sentiment is improving. News and Social Media3.8 / 5News Sentiment0.82 News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for Arrowhead Pharmaceuticals this week, compared to 6 articles on an average week.Search Interest16 people have searched for ARWR on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.MarketBeat Follows3 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ARWR Stock News HeadlinesArrowhead Pharmaceuticals to Webcast Fiscal 2025 Third Quarter ResultsJuly 21 at 4:01 PM | businesswire.comArrowhead Pharmaceuticals Initiates Phase 3 YOSEMITE Study of Investigational Zodasiran for the Treatment of Homozygous Familial HypercholesterolemiaJuly 8, 2025 | businesswire.comWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re quietly shipping 30 tons per year from a facility outside San Antonio.July 24 at 2:00 AM | True Market Insiders (Ad)ARWR Arrowhead Pharmaceuticals, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comArrowhead Pharmaceuticals Completes Enrollment in SHASTA-3, SHASTA-4, and MUIR-3 Phase 3 Studies of PlozasiranJune 23, 2025 | finance.yahoo.comJim Cramer on Arrowhead Pharmaceuticals (ARWR): “It Doesn’t Make Any Money”June 5, 2025 | msn.comJim Cramer: Arrowhead Pharmaceuticals Doesn't 'Have The Horses'June 4, 2025 | benzinga.comArrowhead Pharmaceuticals, Inc. (ARWR)’s ARO-ALK7 Enters Phase 1/2a StudyJune 2, 2025 | insidermonkey.comSee More Headlines ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $18.80 at the beginning of 2025. Since then, ARWR shares have decreased by 13.5% and is now trading at $16.26. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced its earnings results on Monday, May, 12th. The biotechnology company reported $2.75 earnings per share for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The biotechnology company earned $542.71 million during the quarter, compared to analyst estimates of $116.27 million. Read the conference call transcript. Who are Arrowhead Pharmaceuticals' major shareholders? Top institutional investors of Arrowhead Pharmaceuticals include Aberdeen Group plc (0.70%), Wealth Effects LLC (0.12%), Platinum Investment Management Ltd. (0.08%) and Pinion Investment Advisors LLC (0.05%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, William D Waddill, Adeoye Y Olukotun, Hongbo Lu and Victoria Vakiener. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), Alliance Resource Partners (ARLP), Tesla (TSLA), Meta Platforms (META), Advanced Micro Devices (AMD) and Netflix (NFLX). Company Calendar Last Earnings5/12/2025Today7/24/2025Next Earnings (Estimated)8/07/2025Fiscal Year End9/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARWR CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees400Year FoundedN/APrice Target and Rating Average Price Target for Arrowhead Pharmaceuticals$43.71 High Price Target$80.00 Low Price Target$17.00 Potential Upside/Downside+170.3%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth17.59Net Income-$599.49 million Net MarginsN/A Pretax Margin-27.93% Return on Equity-45.33% Return on Assets-12.49% Debt Debt-to-Equity Ratio0.31 Current Ratio5.15 Quick Ratio5.15 Sales & Book Value Annual Sales$3.55 million Price / Sales629.04 Cash FlowN/A Price / Cash FlowN/A Book Value$1.54 per share Price / Book10.50Miscellaneous Outstanding Shares138,100,000Free Float132,162,000Market Cap$2.23 billion OptionableOptionable Beta0.93 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:ARWR) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredBREAKING: The House just passed 3 pro-crypto bills!99.8% voted YES on this crypto partnership Kraken—one of the world's biggest crypto exchanges—just picked O...Crypto 101 Media | SponsoredFREE GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...GoldCo Precious Metals | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.